LC
PRLD icon

Lindbrook Capital’s Prelude Therapeutics PRLD Stock Holding History

Lindbrook Capital’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,562
Closed -$11K – 2708
2022
Q1 		$11K Buy
1,562
+1,471
+1,616% +$13.5K ﹤0.01% 1258
2021
Q4 		$1K Buy
+91
New +$1.48K ﹤0.01% 1974

Other funds holding PRLD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Lindbrook Capital's PRLD Position: Q2 2022 in Review

Lindbrook Capital sold out of Prelude Therapeutics (PRLD) in Q2 2022, closing a stake of 1,562 shares — an estimated $11K sold.

Lindbrook Capital first reported a position in PRLD in Q4 2021 and held it in 2 quarters. The position peaked at $11K in Q1 2022. 62 funds tracked by Wall St. Rank hold PRLD as of Q2 2022.

  • Lindbrook Capital reported no remaining Prelude Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Lindbrook Capital sold 1,562 Prelude Therapeutics shares in Q2 2022, an estimated $11K.
  • Lindbrook Capital first reported a position in Prelude Therapeutics in Q4 2021 and held it in 2 quarters.
  • Lindbrook Capital's Prelude Therapeutics position peaked at $11K in Q1 2022.
  • 62 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2022.

Based on Lindbrook Capital's 13F filing for Q2 2022, filed 1 Aug 2022.